RegulatoryAug 11, 2026, 04:13 PM
Gain Therapeutics' Rexaceract IND Authorized; Phase 2 Ahead
AI Summary
Gain Therapeutics announced its Q2 2026 financial results and a significant corporate update. The U.S. FDA authorized the Investigational New Drug (IND) application for rexaceract, paving the way for Phase 2 clinical development in Q3 2026. The company also reported positive Phase 1b data for rexaceract and progress on GT-04686, its second allosteric modulator. For Q2 2026, the company reported a net loss of $0.11 per share and ended the quarter with $13.1 million in cash.
Key Highlights
- FDA authorized Investigational New Drug (IND) application for rexaceract.
- Phase 2 clinical trial for rexaceract expected to begin in Q3 2026.
- GT-04686 is moving towards IND-enabling studies for clinical development.
- Net loss for Q2 2026 was $0.11 per share, compared to $0.19 in Q2 2025.
- R&D expenses decreased to $2.1 million in Q2 2026 from $2.8 million in Q2 2025.
- Cash and cash equivalents were $13.1 million as of June 30, 2026.
- Dr. Joanne Taylor promoted to CSO; Terenzio Ignoni promoted to COO.
Price Impact
More from GANX